Flexbiotech Inc
Capital Timeline
Capital this company has received, each line traceable to a primary record. Amounts are obligations, not contract ceilings.
A blank stage means the data is not ingested yet, not that the money stopped there.
Across the lifetime of these contracts, $307K has been obligated and $93K paid out. $214K has not been disbursed.
Cumulative from contract start through 2026-08-17. The total above covers only the transactions ingested in the tracking window — a different measure.
- National Institutes of Health$01
Why It Matters
Not enough signal yet to assess this company's relevance to Japanese firms.
Events
Events used as evidence for Stage / LCI. Facts and interpretation are recorded separately.
FLEXBIOTECH INC — Grant R43CA298696
MOLECULAR SCREENING FOR HUMAN PAPILLOMA VIRUS (HPV) ASSOCIATED WITH CERVICAL CANCERS IN LMIC ENVIRONMENTS - ABSTRACT HUMAN PAPILLOMAVIRUS (HPV) CAUSES CERVICAL CANCER, ANOGENITAL CANCERS, AND A SUBSET OF OROPHARYNGEAL CANCERS, WITH OVER 350,000 DEATHS PER YEAR GLOBALLY. THE WORLD HEALTH ORGANIZATION GUIDELINES FOR SCREENING OF CERVICAL CANCER RECOMMEND USING A STRATEGY OF SCREENING WITH AN HPV TEST INSTEAD OF CYTOLOGY OR VISUAL INSPECTION WITH ACETIC ACID (VIA) FOR WOMEN WITH A PRIORITY AGE 30-49. IN MANY UNDERSERVED LOW- AND MIDDLE- INCOME COUNTRIES (LMICS), HPV TESTING MAY BE AVAILABLE IN CITIES BUT MORE LIMITED IN RURAL VILLAGES WITHOUT READY ACCESS TO CLINICAL LABORATORY FACILITIES, DUE TO COST AND LOGISTICAL BARRIERS. TO ADDRESS THIS GAP, WE DEVELOPED AND TESTED A PORTABLE, NOVEL ISOTHERMAL TEST CALLED SPRINT-HPV (SIMPLE, PORTABLE, AND RAPID ISOTHERMAL NUCLEIC- ACID TEST) FOR THE SIMULTANEOUS DETECTION OF HPV16, HPV18, AND NINE OTHER HIGH-RISK SUBTYPES FROM CERVICAL FLUID. SPRINT-
Timeline
No timeline articles for this company yet.